Superior Variant Resolution
Variants of unknown significance (VUS) can make it difficult for healthcare providers to deliver clear test results to their patients. Ambry's best-in-class variant assessment program is dedicated to resolving VUS to give you and your patients clarity.
Learn more about our variant classification.
Expert Variant Assessment Team
Our reporting, variant, and translational genomics teams bring >120 years of combined experience giving your patient the best chance at getting clarification of uncertain results.
Ambry’s scientists are actively involved with international variant experts, collaborators, and clinicians, to share data and enhance our understanding of variants worldwide.
Ambry’s Translational Genomics (ATG) Lab
Ambry is the only laboratory to provide complimentary studies that produce novel evidence to reduce variants of unknown significance (VUS) so that you can provide clear results to patients.
We offer specialized studies, such as targeted RNA analysis of splicing variants and RNA/DNA tandem analysis, providing the necessary data points to better define whether a VUS is benign (normal variation) or pathogenic (disease-causing).
Industry-Leading Database
Over 1.5 million tests completed means a large database to leverage for test optimization and variant assessment.
Sample for Life
Continued review of variants enabled us to reclassify > 650 variants in 2017 alone, bringing further clarity to patients and families who may have received a VUS result.
Family Studies Program
Follow-up testing of appropriate family members which can provide additional, powerful information to aid in VUS resolution.